Friday, December 31, 2010

Mencari Keberkatan Masa



Menjelang tahun baru, ramai yang menyambutnya. Samada hari pertama Januari ataupun Muharram, Islam tidak pernah menetapkan sambutan khusus buat tahun baru.
Tiada ibadat khas sempena tahun baru seperti solat tahun baru, atau puasa tahun baru. Ya, tidak menjadi masalah jika manusia ingin menyiapkan diri mereka menghadapi tahun baru. Mungkin mereka ingin menetapkkan sasaran, perancangan dan idaman.
Jika perancangan itu untuk kebaikan, seseorang akan memperolehi pahala. Begitulah sebaliknya. Jika tahun baru tidak datang pun, waktu dan hari tetap terus berputar dan tiada bezanya antara tahun lepas dan tahun ini. Ia terus berjalan seperti biasa sehingga sampai detik ia berhenti.

Academic Bureau Voice Out!

Assalamualaikum warahmatullahi wabarakatuh.
Beloved brothers and sisters,
Academic bureau of Rx8 generation is looking forward to assist you for your journey towards excellence. We try so hard to make sure that your journey will become smooth and your study will become more comfortable.

Pertaining the lecture notes photocopies, we really hope that all of you can cooperate to pay as soon as possible due to the financial condition of our batch. As you have been mentioned before, we could probably owe the photocopy centre for some amount of money as our class fund couldn't be able to cover all of that. Since our scholars have been credited into our account currently, so I do hope each of us could bare to pay immediately to our respected treasurer (nur izzat & maisarah). Any objection about the amount that you should pay, you can directly ask us (ridzuan zaidi & siti nuraidah).

May Allah bless all of us.

For this entry, we are very pleased to share a number of universities that you can possibly apply for continuing your postgraduate studies in the future. This is due to the fact that they have school of pharmacy and offer pharmacy related courses for foreign students like Malaysians.

The University of Sydney

One of the top universities in the world. Ranked in the Top 50 Best Universities in the world recently.


The University of Queensland, Brisbane

Also one of the top universities in the world best on their research and facilities. In fact, the requirement of English language is quite high for those who wish to study there.
Our beloved deputy dean of academic, Dr. Che Suraya was one of the students.

Monash University, Melbourne

Located in Melbourne, one of the metropolitan cities in Australia.
This university is just next to University of Melbourne.
Besides, it also has several offshore campus like the one in Subang Jaya.


Curtin University of Technology, Perth, Western Australia

This university is named after Australian's former prime minister, John Curtin.
As it is located in Perth, students may experience a number of beautiful beaches there.
It also has an offshore campus in Sarawak.



University of South Australia (UniSA), Adelaide

This university is located in a very calm town just in South Australia territory. But it's really good to study there as your life will not stuck for the reason of high daily expenses.


University of Tasmania, Tasmania Island

This university is located in the largest island in Australia and the coldest part of that country.
For those who wish to explore and experience snowing area in that country the most,
then this is the right place.



University of Otago, New Zealand

This is the only university in New Zealand that offers pharmacy course for foreign students.
This university physically has the most beautiful buildings other than the University of Sydney based on its arts compared to other universities that I mentioned before.

These probably could be a booster for you to strive harder and study smartly.
For your extra information, CGPA above 3.0 may qualify you to apply for master and CGPA above 3.65 may qualify you to apply for PhD program directly without doing master.

So, what are you waiting for? Let's begin now!

We will introduce you with other universities offering pharmacy courses
in Europe and US next time! Jazakumullah.

Monday, December 27, 2010

QUIZ WEEK 3

salam..

these are the quizzes that have been confirmed so far 4 this week:
pharmacognosy (2%): wed (29/12), 1.15 pm, exam hall 2- lecture 1-3
pharmaceutical analysis: thursday (30/12)
neutraceutical: no specific day yet.. (ari jumaat kot.. hehe..)
respiratory: NEXT WEEK....

all the best for all of us.. may His blessings be with us.. InsyaAllah..:)

Thursday, December 23, 2010

timetable 24/12 (Friday)

ATTENTION!!!: sudden change in 2morrow schedule:
8am-dr kausar
9am-dr abu bakar
10am-briefing with mdm rohani
10.30am-dr saifullah
11.30am-xconfrm lg
3-5pm-dr kausar..

~this is the latest update, but we will inform 2 u time to time on the changes in timetable (if any) esp kelas yg ptg 2..

Wednesday, December 22, 2010

Borang Maklumat Diri

Kepada semua nama di bawah, sila isi Borang Maklumat Diri secepatnya. Kerjasama anda didahului dengan jutaan terima kasih.

*Sila khabarkan hal ini kepada kawan sebilik/kawan baik/kawan serumah atau sesiapa sahaja yang anda tahu namanya tertulis di bawah.

BROTHERS

AHMAD FAWWAZUDDIN B. ROZAKI
MUHAMMAD NAZMI B. ABDUL WAHAB
MOHD HISHAMUDIN BIN MOHD JINAL
SAYED MOHD SAUFI FAHMI B. SAYED ABDUL KADIR
MOHD SAFUAN B. SUDIN
MUHAMMAD AIDIL IZMI B. UMAR BAKI
AHMAD FATIHI B. MAKHTAR
 MAHMUD ULWAN B. SALEHAN
AMIRUL BUKHARI B. ISMAIL

Tuesday, December 21, 2010

Final Reminder

To those who do not fill in your info yet, please do so A.S.A.P.

The form can be reached HERE

Your cooperation is highly needed.

Prevent your name from being displayed here.

+ Please inform your friend about this.

+ Facilitate us, so that we can facilitate you. 

Spread da love.
***************************

Sunday, December 19, 2010

Wawasan Rx8

Rx8 IIUM

ditulis oleh: As-Syafiq

‘Rx’, satu gelaran sinonim yg diberikan kepada setiap batch untuk ijazah farmasi di UIAM Kuantan. Tuntas, panggilan ‘Rx8’ yg sudah sebati dengan batch ke-8 kemasukan 2009 ini menjadi kebanggaan kami sebagai batch Rx8.

Menyingkap tirai sejarah Rx8 yang bermula dengan 103 orang mahasiswa dan mahasiswi pada Julai 2009, kini, tetap berdiri kukuh dengan jumlah 105 orang mahasiswa dan mahasiswi pada Julai 2010. Dengan bilangan ahli keluarga yang ramai, Rx8 penuh dengan ragam dan lagat yang pelbagai, memeriahkan suasana, serta saling melengkapi antara satu sama lain.

Friday, December 17, 2010

Latest Info Update

Our class committee is collecting the latest info of our class members. This is very substantial to ensure the info and announcement about lecture, society and kulliyyah can be conveyed to everybody. Hence, your cooperation to fill in the form HERE is highly needed.

Due date:
-Sunday
-10 p.m

Those names who do not doing so will be displayed in this blog.

Subcomm Year 2 Sem 2



p/s: sory sgt atas kekeliruan yg timbul

Wednesday, December 15, 2010

interbatch games

salam =_=

attention to all rx8th!!!

insyaAllah, our annual sports interbatch will be held on
26th dec-31th december 2010...so, all the players must be prepared and give full commitment and cooperation to our batch and others.

BROTHER
  • FUTSAL
  • BASKETBALL
  • PING PONG (single and double)
  • BADMINTON (single and double)
  • VOLLEYBALL
SISTER
  • FUTSAL
  • BASKETBALL
  • NETBALL
  • PING PONG (double)
  • BADMINTON (double)
  • VOLLEYBALL
TQ =)

I-CORP’S Lolly Chocholates Dedication Request


Assalamualaikum wbt


Hola everyone! Our annual sports interbatch competition is coming real soon! Y not take this opportunities wishing your fellow team mates “Best OF Lucks” or your rivals for a really good fight. Not necesserily for interbatch only, you may also order something special for yourself, friends, bestfriends, classmates, housemates, roomates, etc as your appreciation to them for being friends since you all know each other from CFS until now by giving them a gift of exclusively hand-crafted lolly chocolates only by one of the IPha Bureau,

I-Corp

Chocolate stimulates endorphin production that affect your feelings and behavior by making you happy. Hence, it counteracts depression. Your stress-free life helps you maintain a youthful disposition, both physically and mentally. So what are you waiting for? give them a gift of lolly chocolates or simply buy for yourselves (no one knows anyway). ~Cheers~


PACKAGES OFFERED :-

(real product may be of different colour combination)



PACKAGE A

(Smiley Lolly Chocs)

RM 2.50

PACKAGE B

(Rose Lolly Chocs)

RM2.50


PACKAGE C

(Soccer/Futsal Lolly Chocs)

RM 3.00


PACKAGE D

(Basketball Lolly Chocs)

RM 3.00


PACKAGE E

(Baseball Lollyn Chocs)

RM 3.00

PACKAGE F

(Shirt Lolly Chocs)

RM 3.00



All lolly chocs are made from Beryl’s compound dark and milk chocolates.

All lolly chocs are filled either with almond/crushed oreo (subject to availability).


Size, decoration and colour are of chocolatier’s interest (multicolour for sure!).

Weight: ±70g/each aka L size.


All lolly chocs will be delivered to your lecture hall/audi by 27/12.


HURRY UP! It is only 3 days! You might taste the good of beautiful and colourful chocholates only once in lifetime from Ipha! Dont be regrets!



*please fill in your particulars in the form that will be distributed in class from 15/12 - 17/12 2010.


*please submit complete form and money to Atiqah HY(Rx9) or Syahmi(Rx by 17/12/2010

FDA Approves Tesamorelin for HIV Lipodystrophy


From MedscapeCME Clinical Briefs > FDA Approvals and Safety Changes for CME

News Author: Yael Waknine
CME Author: Yael Waknine
CME/CE Released: 11/24/2010; Valid for credit through 11/24/2011

November 24, 2010 — The US Food and Drug Administration (FDA) has approved tesamorelin acetate injection (Egrifta; Theratechnologies, Inc, and marketed by EMD Serono) as the first and only treatment indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.
Tesamorelin is a synthetic analog of growth hormone–releasing factor — a hypothalamic peptide that acts on pituitary cells in the brain to stimulate the production and release of endogenous growth hormone.
"The FDA recognizes the need for therapies to treat patients with HIV-lipodystrophy," said Curtis Rosebraugh, MD, MPH, director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research, in an agency news release. "The presence of excess fat with this condition may contribute to other health problems as well as affect a patient's quality of life, so treatments that demonstrate they are safe and effective at treating these symptoms are important."
FDA approval followed a positive endorsement from the Endocrinologic and Metabolic Drugs Advisory Committee and was based on data from 2 multicenter, randomized, double-blind, placebo-controlled phase 3 studies of 816 patients, showing that once-daily treatment with tesamorelin significantly reduced visceral adipose tissue (VAT) at 26 weeks.
Mean VAT at baseline ranged from 178 cm2 to 186 cm2 for the active-treatment group and 171 cm2 to 195 cm2for patients randomly assigned to placebo, as assessed by computed tomography scan at the L4–L5 vertebral level.
Computed tomography scan results of the first study showed that tesamorelin therapy yielded an 18% least-squares mean decrease from baseline in VAT compared with an increase of 2% for placebo (Δ, −20%; 95% confidence interval [CI], −24% to −15%). In the second study, tesamorelin-treated patients experienced a likewise significant 14% decrease from baseline in VAT compared with a 2% decrease among those given placebo (Δ, −12%; 95% CI, −16% to −7%).
Both studies also showed significant decreases in VAT as measured by least-squares mean decreases from baseline in waist circumference (study 1, −3 cm vs −1 cm; Δ, −2 cm; 95% CI, −2.8 cm to −0.9 cm; study 2, −2 cm vs −1 cm; Δ, −1 cm; 95% CI, −2.5 cm to −0.3 cm).
The decreases in VAT and waist circumference were sustained in patients who received extended therapy with tesamorelin for 52 weeks.
The recommended dose of tesamorelin is 2 mg (2 vials) injected subcutaneously once daily in the abdomen. Adverse events most commonly reported in tesamorelin-treated study patients included arthralgia (13% vs placebo, 11%), pain in extremity (6.1% vs 4.6%), myalgia (5.5% vs 1.9%), injection-site erythema (8.5% vs 2.7%), injection-site pruritus (7.6% vs 0.%), and peripheral edema (6.1% vs 2.3%).
FDA officials note that the long-term cardiovascular benefit and safety of tesamorelin have not been studied, and there are no data to support improved compliance with antiretroviral therapies. Also, tesamorelin should not be used for weight-loss management.
"As HIV-infected patients are living longer, a substantial number may develop metabolic complications associated with HIV, such as abdominal lipohypertrophy," said Morris Schambelan, MD, professor of medicine from the University of California–San Francisco, in a company news release. "With the approval of Egrifta, doctors are now able to provide appropriately selected patients with a treatment option shown to reduce [VAT]."
Because tesamorelin induces the release of endogenous growth hormone, it should not be used in patients with active malignancy, whether newly diagnosed or recurrent. Tesamorelin increases serum levels of insulin-like growth factor 1 (IGF-1), which has an unknown effect on the development or progression of malignancies. Discontinuation of therapy should be considered in patients with persistent IGF-1 elevations greater than 3 standard deviations, particularly if the efficacy response is not robust. In clinical trials, IGF-1 levels were measured every 3 months.
Tesamorelin therapy may also result in glucose intolerance and an increased risk for diabetes mellitus. Glucose status should be carefully evaluated before initiating therapy and monitored periodically thereafter. Caution is advised when treating patients who develop glucose intolerance or diabetes, and discontinuation of therapy should be considered in those who do not demonstrate a clear efficacy response. Diabetic patients should be monitored at regular intervals for the potential development or worsening of retinopathy.
Treatment with tesamorelin is contraindicated in patients with disruption of the hypothalamic–pituitary axis resulting from hypophysectomy, hypopituitarism, or pituitary tumor/surgery; active malignancy; or pregnancy and in patients with known hypersensitivity to tesamorelin and/or mannitol.
The safety and efficacy of tesamorelin have not been established in pediatric patients and in those with renal or hepatic impairment; discontinuation of therapy should be considered in critically ill patients.
As a condition of approval, the company is required to conduct a clinical trial to assess whether tesamorelin has an effect on diabetic retinopathy, and a long-term observational safety study for a single-vial formulation of the drug (tesamorelin).
More information on this drug is available on the FDA Web site.

Clinical Implications

  • The FDA has approved tesamorelin acetate injection for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Clinical data have shown a mean decrease of 14% to 18% from baseline in VAT at 26 weeks, an improvement that was sustained in patients who received treatment for 52 weeks.
  • The recommended dose of tesamorelin is 2 mg injected subcutaneously once daily in the abdomen. Adverse events most commonly include arthralgia, pain in the extremity, myalgia, injection-site erythema and pruritus, and peripheral edema. Long-term cardiovascular benefit and safety are unknown, and there are no data to support improved compliance with antiretroviral therapy.
  • Tesamorelin is contraindicated in patients with disruption of the hypothalamic-pituitary axis, active malignant disease, hypersensitivity to the drug or to mannitol, or pregnancy. Discontinuation of therapy should be considered for patients with persistent serum IGF-1 elevations of more than 3 SDs who lack a robust response. Caution is advised in those who develop glucose intolerance or diabetes, and discontinuation of therapy should be considered in those who do not demonstrate a clear efficacy response.

Code untuk subject

Monday, December 13, 2010

Timetable Week 1 & 2


Register n Add/Drop


PHM 2112
Physical Pharmacy II

PHM 2222
Pharmacognosy

PHM 2232
Pharmaceutical Analysis II

PHM 2243
Body System I : Cardiovascular & Haematology

PHM 2252
Body System II : Respiratory

PHM 2262
Body System III : Gastrointentestinal & Hepatobiliary Systems

PHM 2272
Body System IV : Urinary System

elektif x tahu kod. siapa tahu tlg tambah kat komen. tQ


Sunday, December 12, 2010

Pengundian Tahun 2 Sem 2



Salam.

Klik link ini untuk mengundi.

Tarikh tutup : 12 malam 14 Disember (tgh malam esok)

Selamat2!





Marilah mari, pergi mengundi..
Tunaikan kewajipan anda pada rx8..
Sorang undi sekali shj!

Friday, December 10, 2010

Nomination

Salam kasih sayang rx8,
dengan lafaz
Assalamualaikum warahmatullahi wabarakatuh
biarlah orang mengucapkan salam sebagai adat, tapi kita mengucapnya sebagai ibadah.
Salam jumaat .

Sekadar nak bgtahu flow2 nomination utk rx8 sem 2 tahun 2 kite ni
1. usul nama stp post oleh stp mainboard 3-3 sem yang dah lepas
2. shorlist
3. undi online

sekarang ni kita dah sampai kat no 2.

jadi, makin lmbt shortlist makin lmbt undian start, sbb indvidu2 terlibat pn ade urusan lain.
ok,
harap maklum